01 10Letairis
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 314
2019 Revenue in Millions : 618
Growth (%) : -49
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 206
2020 Revenue in Millions : 314
Growth (%) : -34
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 196
2021 Revenue in Millions : 206
Growth (%) : -5
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 142
2022 Revenue in Millions : 196
Growth (%) : -28
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 595
2014 Revenue in Millions : 700
Growth (%) : 18%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 819
2015 Revenue in Millions : 700
Growth (%) : 17
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 887
2016 Revenue in Millions : 819
Growth (%) : 8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 943
2017 Revenue in Millions : 887
Growth (%) : 6%
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : 14.40%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 618
2018 Revenue in Millions : 943
Growth (%) : -34
LOOKING FOR A SUPPLIER?